Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (141-150 of 367) with videos related to

Pageof 37
Sort By:
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
Plos One|July 31, 2024
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancerKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Journal of Cancer Research and Clinical Oncology|June 26, 2024
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?Melda Yeghaian, Teresa M Tareco Bucho, Melissa de Bruin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 7, 2011
Nutrition during trimodality treatment in stage III non-small cell lung cancer: not only important for underweight patientsBarbara S van der Meij, Erik C J Phernambucq, Geert M Fieten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancerMassimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, et al.
BMC Cancer|March 15, 2023
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancerHanieh Abedian Kalkhoran, Juliëtte Zwaveling, Bert N Storm, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 7, 2011
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysisPatsuree Cheebsumon, Linda M Velasquez, Corneline J Hoekstra, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2010
Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancerAstrid A M van der Veldt, N Harry Hendrikse, Hendrik J Harms, et al.
Molecular Imaging and Biology|February 28, 2016
Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and DelineationFloris H P van Velden, Gerbrand M Kramer, Virginie Frings, et al.
International Journal of Technology Assessment in Health Care|October 24, 2002
Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approachPaul Verboom, G Judith M Herder, Otto S Hoekstra, et al.
Pageof 37

Showing results (141-150 of 367) with videos related to

Sort By:
Pageof 37
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
Plos One|July 31, 2024
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancerKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Journal of Cancer Research and Clinical Oncology|June 26, 2024
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?Melda Yeghaian, Teresa M Tareco Bucho, Melissa de Bruin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 7, 2011
Nutrition during trimodality treatment in stage III non-small cell lung cancer: not only important for underweight patientsBarbara S van der Meij, Erik C J Phernambucq, Geert M Fieten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancerMassimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, et al.
BMC Cancer|March 15, 2023
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancerHanieh Abedian Kalkhoran, Juliëtte Zwaveling, Bert N Storm, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 7, 2011
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysisPatsuree Cheebsumon, Linda M Velasquez, Corneline J Hoekstra, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2010
Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancerAstrid A M van der Veldt, N Harry Hendrikse, Hendrik J Harms, et al.
Molecular Imaging and Biology|February 28, 2016
Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and DelineationFloris H P van Velden, Gerbrand M Kramer, Virginie Frings, et al.
International Journal of Technology Assessment in Health Care|October 24, 2002
Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approachPaul Verboom, G Judith M Herder, Otto S Hoekstra, et al.
Pageof 37